semaglutide diabetes trial 2·4 mg once a week in adults with overweight or obesity, and type 2 (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 Semaglutide and Cardiovascular Outcomes in

Diets become easier to stick to because you have sufficient energy and you can get more fat burning power out of your workouts

Appetite hormones such as ghrelin rise, fullness hormones such as leptin fall, and metabolism slows slightly to conserve energy

Reasons may include: Dose too low Irregular injection schedule Diet and lifestyle inconsistencies Underlying hormonal or metabolic issues If progress is slower than expected, a provider may review: Relevant labs and health markers Medication tolerance and dosing Nutrition, movement, sleep, and stress patterns Whether the care plan should continue, change, or stop This is why provider-guided monitoring can help personalize care and support safer treatment decisions